BI Asset Management Fondsmaeglerselskab A S Acquires 17,678 Shares of Insulet Corporation $PODD

BI Asset Management Fondsmaeglerselskab A S grew its holdings in Insulet Corporation (NASDAQ:PODD) by 137.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 30,534 shares of the medical instruments supplier’s stock after acquiring an additional 17,678 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Insulet were worth $8,679,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Glenmede Investment Management LP boosted its position in shares of Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares during the period. Curi Capital LLC raised its stake in Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after purchasing an additional 36 shares in the last quarter. WINTON GROUP Ltd raised its stake in Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after purchasing an additional 37 shares in the last quarter. Camarda Financial Advisors LLC raised its stake in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares in the last quarter. Finally, Larson Financial Group LLC raised its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares in the last quarter.

Insider Activity

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.36% of the stock is owned by corporate insiders.

Insulet Stock Up 4.7%

Shares of NASDAQ PODD opened at $153.22 on Friday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The company has a market cap of $10.61 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 1.21 and a beta of 1.13. Insulet Corporation has a 12 month low of $140.63 and a 12 month high of $354.88. The stock has a 50-day moving average price of $175.73 and a two-hundred day moving average price of $238.90.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the previous year, the firm earned $1.02 earnings per share. The business’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts forecast that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PODD has been the subject of a number of analyst reports. Stifel Nicolaus dropped their price target on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $280.00 price target on shares of Insulet in a research note on Wednesday, May 27th. Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Evercore dropped their price target on Insulet from $240.00 to $200.00 in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. dropped their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $252.04.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.